

- C1
27. (Amended) A composition comprising a first and second component, wherein the first component is a vector comprising more than one DNA sequence selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 antigen, a DNA sequence encoding a Dengue virus serotype 2 antigen, a DNA sequence encoding a Dengue virus serotype 3 antigen, or a DNA sequence encoding a Dengue virus serotype 4 antigen and wherein the more than one DNA sequences are under the transcriptional control of a T7 RNA polymerase promoter and the second component is a recombinant Modified Vaccinia Ankara (MVA) virus comprising a DNA sequence encoding T7 RNA polymerase.

Please add the following new claims:

- CA
- Sub D4
32. (New) A cell containing the composition of claim 27.
33. (New) A recombinant Modified Vaccinia Ankara (MVA) virus comprising more than one DNA sequence selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 preM antigen, a DNA sequence encoding a Dengue virus serotype 2 preM antigen, a DNA sequence encoding a Dengue virus serotype 3 preM antigen, and a DNA sequence encoding a Dengue virus serotype 4 preM antigen.
34. (New) The recombinant Modified Vaccinia Ankara (MVA) virus of Claim 33 comprising a DNA sequence encoding a Dengue virus serotype 1 preM antigen, a DNA sequence encoding a Dengue virus serotype 2 preM antigen, a DNA sequence encoding a Dengue virus serotype 3 preM antigen, and a DNA sequence encoding a Dengue virus serotype 4 preM antigen.
35. (New) A recombinant Modified Vaccinia Ankara (MVA) virus comprising more than one DNA sequence selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 E antigen, a DNA sequence encoding a Dengue virus serotype 2 E antigen, a DNA sequence encoding a Dengue virus serotype 3 E antigen, and a DNA sequence encoding a Dengue virus serotype 4 E antigen.
36. (New) The recombinant Modified Vaccinia Ankara (MVA) virus of Claim 35 comprising

a DNA sequence encoding a Dengue virus serotype 1 E antigen, a DNA sequence encoding a Dengue virus serotype 2 E antigen, a DNA sequence encoding a Dengue virus serotype 3 E antigen, and a DNA sequence encoding a Dengue virus serotype 4 E antigen.

- CJ
37. (New) A recombinant Modified Vaccinia Ankara (MVA) virus comprising more than one DNA sequence selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 NS-1 antigen, a DNA sequence encoding a Dengue virus serotype 2 NS-1 antigen, a DNA sequence encoding a Dengue virus serotype 3 NS-1 antigen, and a DNA sequence encoding a Dengue virus serotype NS-1 antigen.
- Sub D5
38. (New) The recombinant Modified Vaccinia Ankara (MVA) virus of Claim 37 comprising a DNA sequence encoding a Dengue virus serotype 1 NS-1 antigen, a DNA sequence encoding a Dengue virus serotype 2 NS-1 antigen, a DNA sequence encoding a Dengue virus serotype 3 NS-1 antigen, and a DNA sequence encoding a Dengue virus serotype NS-1 antigen.

REMARKS

Claims 15-31 are pending in this application. Claim 27 has been amended to correct an inadvertent typographical error. New claims 32-38 have been added. Support for the new claim may be found throughout the specification. For example support for claim 32 may be found at page 8, lines 30-31; page 9, lines 1-7 and support for claims 33-38 may be found at page 6, lines 6-11. A marked up version showing the amendments to the claims and the newly added claims is attached as Exhibit A. A copy of the currently pending claims is attached as Exhibit B. Reconsideration of the application in view of the following remarks is respectfully requested.

REJECTIONS UNDER 35 U.S.C. § 112, SECOND PARAGRAPH

Claims 27-31 stand rejected under 35 U.S.C. §112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which